At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood
In Brief
A Phase 4 clinical trial evaluating Subcutaneous depot medroxyprogesterone acetate for Contraception. Completed, enrolled 401 participants across 2 sites.
Detailed Summary
This randomized clinical trial will study subcutaneous depot medroxyprogesterone acetate (DMPA sc) self-administration at two Planned Parenthood affiliates serving diverse patient populations. Prior studies demonstrate that DMPA self-injection is safe, effective, feasible, and acceptable for women and adolescents. A total of 400 female patients (ages 15-44) requesting DMPA will be randomized to self-administration of DMPA sc or clinic administration (usual care). Subjects will be followed for one year. The primary study outcome is DMPA continuation at one year by self-report in both study arms. Secondary outcomes include patient-reported satisfaction with treatment; satisfaction with home use; and costs associated with contraceptive care. The investigators hypothesize higher continuation rates among self-injection users compared to patients who receive standard care. Secondary exploratory hypotheses include higher patient satisfaction and lower costs associated with contraceptive care among self-injection users.
Study Details
Timeline
Interventions
Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.